iShares Biotechnology ETF
253 hedge funds and large institutions have $2.51B invested in iShares Biotechnology ETF in 2013 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 86 increasing their positions, 76 reducing their positions, and 21 closing their positions.
110% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 21
25% more call options, than puts
Call options by funds: $184M | Put options by funds: $147M
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
13% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 76
11% more capital invested
Capital invested by funds: $2.26B → $2.51B (+$250M)
9% more funds holding
Funds holding: 232 → 253 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$24.7M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$16.5M |
| 4 |
LPL Financial
San Diego,
California
|
+$9.79M |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$9.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$92.5M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$65M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$53.3M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$33M |
| 5 |
JP Morgan Chase
New York
|
-$15.9M |
IBB Hedge Fund Activity: Q3 2013 in Review
253 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2013, worth a combined $2.51B — up 11% from $2.26B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new IBB positions and 21 closed out — a net gain of 23 holders — while 86 added to existing stakes and 76 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28.3M. The largest seller was Morgan Stanley, cutting an estimated $92.5M.
- 253 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2013, up from 232 in Q2 2013.
- Funds reported $2.51B of iShares Biotechnology ETF stock for Q3 2013, up 11% quarter-over-quarter.
- 44 funds opened new iShares Biotechnology ETF positions in Q3 2013 and 21 closed out, a net change of +23 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2013 was Fidelity Investments, an estimated $28.3M added.
- The largest iShares Biotechnology ETF seller in Q3 2013 was Morgan Stanley, an estimated $92.5M sold.
Based on aggregated 13F filings for Q3 2013.